Payment overview · 2025
General Payments
$66,234.67
252 reported records · 18 companies
Healthcare provider profile · identity verified
Rizwan K Alimohammad, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ALBANY, NY · NPI 1750546008
Verified facts
What the public records show
CMS Open Payments records show Rizwan K Alimohammad, MD received $66,234.67 in general payments during 2025 across 252 reported records.
Boston Scientific Corporation accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 680 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35,162.06 | 53.1% | 92 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $12,990.40 | 19.6% | 25 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $6,979.03 | 10.5% | 23 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $5,604.49 | 8.5% | 18 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $2,750.00 | 4.2% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $1,326.75 | 2.0% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $585.44 | 0.9% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $256.60 | 0.4% | 38 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $196.72 | 0.3% | 14 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $195.65 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.27 | 0.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.35 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.86 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.99 | 0.0% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $17.90 | 0.0% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.82 | 0.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $15.13 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,625.00 | 28 |
| Consulting Fee | $14,600.00 | 7 |
| Food and Beverage | $5,746.57 | 211 |
| Travel and Lodging | $3,263.10 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $22,200.00 | 11 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $12,990.40 | 25 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc., Medical Device Business Services, Inc. | $9,671.38 | 22 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $8,175.00 | 5 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $5,604.49 | 18 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $3,394.14 | 13 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $1,326.75 | 5 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $736.36 | 32 | 2025 |
Source payment records
|
|||||
| myLUX Patient Kit with mobile device Normalized: mylux patient kit with mobile device |
Device | Boston Scientific Corporation | $288.54 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $248.49 | 37 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $195.65 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $187.95 | 10 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $81.97 | 4 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $68.65 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.27 | 4 | 2025 |
Source payment records
|
|||||
| OCTARAY MAPPING CATHETER Normalized: octaray mapping catheter |
Device | Biosense Webster, Inc. | $57.65 | 3 | 2025 |
Source payment records
|
|||||
| Baylis Medical Company Radiofrequency Puncture Generator Normalized: baylis medical company radiofrequency puncture generator |
Device | Boston Scientific Corporation | $54.25 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $52.61 | 10 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| FARAWAVE Normalized: farawave |
Device | Boston Scientific Corporation | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $10.03 | 1 | 2025 |
Source payment records
|
|||||
| FEMOSTOP Normalized: femostop |
Device | Abbott Laboratories | $9.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 680 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
163 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
680 | 232 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 680 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 562 | 192 |
| Metoprolol Succinate | Metoprolol Succinate | 536 | 199 |
| Lisinopril | Lisinopril | 330 | 109 |
| Furosemide | Furosemide | 201 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 57 |
| Amiodarone Hcl | Amiodarone Hcl | 170 | 73 |
| Entresto | Sacubitril/Valsartan | 163 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 59 |
| Losartan Potassium | Losartan Potassium | 152 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 43 |
| Carvedilol | Carvedilol | 123 | 42 |
| Dofetilide | Dofetilide | 121 | 38 |
| Nadolol | Nadolol | 114 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 37 |
| Xarelto | Rivaroxaban | 91 | 25 |
| Bumetanide | Bumetanide | 89 | 36 |
| Potassium Chloride | Potassium Chloride | 73 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 24 |
| Nifedipine Er | Nifedipine | 51 | 19 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Spironolactone | Spironolactone | 45 | 21 |
| Nitroglycerin | Nitroglycerin | 36 | 22 |
| Ezetimibe | Ezetimibe | 34 | 13 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Valsartan | Valsartan | 30 | 12 |
| Atenolol | Atenolol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66,234.67 · 252 records | Boston Scientific Corporation | ACCOLADE SR, AREXVY, ATRICLIP LAA EXCLUSION SYSTEM, Assure WCD, Attruby, Barostim Neo System, Baylis Medical Company Radiofrequency Puncture Generator, CARTO 3, ELIQUIS, EMBLEM MRI S-ICD, ENTRESTO, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, FARAPULSE, FARAWAVE, FEMOSTOP, FUROSCIX, General - Brady, Hillrom - Carnation Ambulatory Monitor, INGEVITY MRI, INGEVITY+, LATITUDE Communicator Power Supply, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, MITRACLIP, MYCARELINK, NAVITOR, OCTARAY MAPPING CATHETER, PERCLOSE PROSTYLE, REPATHA, Rapiblyk, SAPIEN 3 Ultra RESILIA, myLUX Patient Kit with mobile device | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error